This project plans to leverage advanced multi-omics and computational biology techniques to explore and develop a set of clinical pan-cancer blood early diagnosis markers (panels). Additionally, it aims to create corresponding single-molecule diagnostic reagent kits for pan-cancer proteins and develop more cost-effective and practical supporting reagents and technical platforms.
Proteins can be secreted into the blood or other body fluids under normal physiological or pathological conditions, making them crucial molecular markers for clinical assessment of health status, early disease screening, diagnosis, and prognosis monitoring. Blood samples are vital in clinical diagnosis and precision medicine research due to their easy accessibility and minimal trauma to the body. As a key medium in the body’s circulatory system, blood carries markers produced in various tissue microenvironments during physiological and pathological processes. Particularly, blood protein markers have been instrumental in diagnosing a range of diseases, including cardiovascular diseases, cancers, infectious diseases, neurodegenerative diseases, and metabolic syndromes.
We are prepared to undertake a rolling 3-year period for dataset collection, development of optimized machine learning algorithms, establishment of multi-center proteomics data panels, and the development of an intelligent detection device.
The goal of this technology is to enable earlier and more accurate cancer diagnosis, thereby improving treatment outcomes and patient survival rates. This project will make single-molecule protein detection more efficient and intelligent, with the potential to significantly impact the fields of medicine and scientific research. The research promises to enhance the accuracy of early cancer diagnosis and provide new technologies for the research and diagnosis of other diseases.